Common use of Exclusive Relationship Clause in Contracts

Exclusive Relationship. During the term of this Agreement, neither RenaGel LLC, GelTex nor Genzyme, nor any of their respective Affiliates shall independently, or with a Third Party, conduct research regarding, or engage in the manufacture, marketing, sale or distribution of, products in the Field and in the Territory other than as part of the Program. In addition, during the two-year period following termination of this Agreement, neither (a) the breaching Party or its Affiliates in the case of termination pursuant to Section 13.2.1 hereof, (b) Genzyme or its Affiliates in the case of termination pursuant to Section 13.2.2 hereof, (c) the terminating Party and its Affiliates in the case of termination pursuant to Section 13.2.3 hereof or (d) the non-terminating Party and its Affiliates in the case of termination pursuant to Sections 13.2.4 and 13.2.5 hereof shall independently, or with a Third Party, conduct research regarding, or engage in the manufacture, marketing, sale or distribution of, products in the Field in the Territory; provided, however, that in the event that this Agreement is terminated pursuant to Section 13.2.3 and the non-terminating Party does not exercise its option under Section 13.3.3(a), then the restrictions set forth in this sentence shall not apply.

Exclusive Relationship. During the term of this AgreementSubject to Section 3.2, neither RenaGel Kallikrein LLC, GelTex nor Genzyme, Dyax nor any of their respective Affiliates shall independently, or with a Third Party, conduct research or development activities regarding, or engage in the manufacture, marketing, sale or distribution of, products in DX-88 and any other protein/peptide product that inhibits the Field and in activity of human plasma kallikrein during the Territory term of this Agreement other than as part of the Program. In addition, during the two-year period following termination of this Agreement, neither (a) the breaching Party or and its Affiliates in the case of termination pursuant to Section 13.2.1 hereof, (b) Genzyme or the terminating Party and its Affiliates in the case of termination pursuant to Section 13.2.2 hereof, (c) the terminating Party and its Affiliates in the case of termination pursuant to Section 13.2.3 hereof or (d) the non-terminating Party and its Affiliates in the case of termination pursuant to Sections 13.2.3 and 13.2.4 and hereof nor (d) Genzyme in the case of termination pursuant to Section 13.2.5 hereof shall independently, or with a Third Party, conduct research regarding, or engage in the manufacture, marketing, sale or distribution of, protein/peptide products in that inhibit the Field in the Territoryactivity of human plasma kallikrein; providedPROVIDED, howeverHOWEVER, that in the event that this Agreement is terminated pursuant to Section 13.2.3 Sections 13.2.2 or 13.2.5 hereof and the non-terminating Party Party, or Dyax in the case of termination pursuant to Section 13.2.5 hereof, does not exercise its option under Section 13.3.3(a)Sections 13.3.2(a) or 13.3.5(a) hereof, then the restrictions set forth in this sentence shall not apply. Notwithstanding the foregoing, nothing herein is intended to restrict Genzyme, Dyax or their respective Affiliates from conducting research or development activities regarding, or engaging in the manufacture, marketing, sale or distribution of, "small molecule" drugs (as defined in Section 1.3).

Exclusive Relationship. During the term of this Agreement, neither RenaGel ATIII LLC, GelTex Genzyme nor GenzymeGTC, nor any of their respective Affiliates shall independently, or with a Third Party, conduct research or development activities regarding, or engage in the manufacture, marketing, sale or distribution of, products comprising tgATIII in the Field and in the Territory other than as part of the Program; *. In addition, during the two-year period following termination of this Agreement, neither (a) the breaching Party or and its Affiliates in the case of termination pursuant to Section 13.2.1 hereof, (b) Genzyme or its Affiliates in the case of termination pursuant to Section 13.2.2 hereof, (c) the terminating Party and its Affiliates in the case of termination pursuant to Section 13.2.3 hereof or (d) the non-non- terminating Party and its Affiliates in the case of termination pursuant to Sections Section 13.2.4 and 13.2.5 hereof shall independently, or with a Third Party, conduct research regarding, or engage in the manufacture, marketing, sale or distribution of, products comprising tgATIII in the Field and in the Territory; provided, however, that in the event that this Agreement is terminated pursuant to Section 13.2.3 hereof and the non-terminating Party does not exercise its option under Section 13.3.3(a)13.3.3 hereof, then the restrictions set forth in this sentence shall not apply. Notwithstanding the foregoing, nothing herein is intended to restrict GTC or Genzyme or their respective Affiliates from conducting research or development activities regarding, or engaging in the manufacture, marketing, sale or distribution of, products that have substantially different biomedical pathways and are targeted to the same indications included hereunder.